Novartis delivered growth on top and bottom line in all divisions in Q3

  • Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
    • Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
    • Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 11% (cc)
    • Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
    • Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure

      • …

/by

Novartis delivered growth on top and bottom line in all divisions in Q3

  • Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
    • Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
    • Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 11% (cc)
    • Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
    • Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure

      • …

/by

Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study

  • 51-week clinical study confirms that  Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile1
  • Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases
  • Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases

 Holzkirchen, September 14, 2017 – Sandoz, a Novartis …

/by

Sandoz proposed biosimilar rituximab accepted for review by the FDA

  • Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis1
  • Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality
  • The global leader in biosimilars, Sandoz has five biosimilars approved worldwide including biosimilar rituximab, which was approved in Europe* in June 20172

Holzkirchen, September 12, 2017 – …

/by

Sandoz invests in major expansion of global headquarters in Holzkirchen, Germany

  • Expected investment will amount to approximately USD 50m
  • Decision to expand underlines confidence in growth potential of business
  • Modern campus facility will promote more collaborative ways of working

Holzkirchen, August 29, 2017 — Sandoz, the generic pharmaceuticals and biosimilars division of Novartis, announced today that it will further expand its global headquarters in Holzkirchen, near Munich. The expected investment will amount to approximately USD 50m.

Sandoz will begin construction of two …

/by

Lancet Haematology publishes data demonstrating Sandoz Rixathon® (biosimilar rituximab) matches efficacy and safety of reference biologic

  • Lancet Haematology publishes data from ASSIST-FL study of Sandoz Rixathon®, in patients with previously untreated advanced follicular lymphoma
  • ASSIST-FL, results of which were first announced in December 2017, achieved its primary endpoint1
  • Rixathon® received European Commission approval for use in all indications of the reference biologic in June 2017 2,3

Holzkirchen, August 29, 2017 – Lancet Haematology has published data from the ASSIST-FL trial demonstrating that the efficacy and safety of …

/by

Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

  • Expanded partnership to help “even the odds” of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana
  • In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10%
  • Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access to healthcare

The digital press release with multimedia content can be accessed here: 

…

/by

Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products

  • Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact:
    • Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications
    • Entresto (USD 110 million) grew steadily driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 9% (cc), driven by Promacta, Tafinlar + Mekinist  and Jakavi
    • Sandoz declined 4% (cc) mainly impacted by increased US pricing pressure
    • Alcon grew 3% (cc) driven by Surgical (+3 …
/by

Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases

  • European Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis
  • Approval of Erelzi provides more treatment options for healthcare professionals and patients and opens another chapter in the Sandoz immunology portfolio
  • Sandoz now has five biosimilars approved in Europe, including biosimilars of some of the world’s leading blockbuster biologics1

Holzkirchen, June 27, 2017 — Sandoz, a Novartis …

/by

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

  • European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases.
  • Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
  • Sandoz now has four biosimilars approved in Europe — more than any other company.1

Holzkirchen, June 19, 2017 — Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European …

/by